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Abstract
Background: Previous observational studies that have examined the association of allopurinol with myocardial
infarction (MI) have provided contradictory results. One study showed that allopurinol reduced the risk, while
another study showed an increased risk with allopurinol. Therefore, our objective was to assess whether allopurinol
use is associated with a reduction in the risk of MI in the elderly.
Method: We used the 2006–2012 5 % random sample of Medicare beneficiaries to study the association of new
allopurinol initiation and the risk of incident MI in a cohort study. Multivariable-adjusted Cox regression models
adjusted for age, gender, race, and Charlson index, in addition to various cardio-protective medications (beta-blockers,
angiotensin-converting enzyme (ACE) inhibitors, diuretics, statins). We calculated hazard ratios (HRs) with 95 %
confidence intervals (CIs). Sensitivity analyses adjusted for coronary artery disease (CAD) risk factors, including
hypertension, hyperlipidemia, diabetes, and smoking.
Results: Of the 29,298 episodes of incident allopurinol use, 1544 were associated with incident MI (5.3 % episodes).
Allopurinol use was associated with reduced hazards of MI, with a HR of 0.85 (95 % CI, 0.77 to 0.95). Compared to no
allopurinol use, longer durations of allopurinol use were associated with a lower HR of MI: 1–180 days, 0.98 (95 % CI,
0.84 to 1.14); 181 days to 2 years, 0.83 (95 % CI, 0.72 to 0.95); and >2 years, 0.70 (95 % CI, 0.56 to 0.88). Other factors
associated with a higher hazard of MI were: age 75 to <85 years and ≥85 years, male gender, higher Charlson index
score, and the use of an ACE inhibitor. Adjustment for CAD risk factors confirmed these findings.
Conclusion: Incident allopurinol use was associated with a reduction in the risk of incident MI in the elderly. Longer
durations of allopurinol use reduced the risk of incident MI incrementally. Future studies should assess the underlying
mechanisms for MI prevention and assess the risk-benefit ratio for allopurinol use.
Keywords: Allopurinol, Myocardial infarction, MI, Risk factor, Pharmacoepidemiology, Elderly, Predictor, Coronary artery
disease, CAD
Background
Coronary artery disease (CAD) is the most common car-
diovascular disease [1]. CAD is the leading cause of
disability [2] and mortality worldwide [3]. Myocardial
infarction (MI) is a common, acute manifestation of
CAD [4]. The case fatality rate of MI remains high, des-
pite a reduction over time [4, 5]. Thus, MI constitutes a
significant public health burden.
Allopurinol is commonly used for the treatment of hy-
peruricemia [6, 7]. Allopurinol is a structural isomer of
hypoxanthine, and its active metabolite, oxypurinol,
competes with hypoxanthine for the enzyme xanthine
oxidase, and leads to the lowering of uric acid produc-
tion. In addition to its urate-lowering effect, recent stud-
ies have suggested other mechanisms of action, some
dependent and some independent of this action [8–15].
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Debate continues whether allopurinol use reduces the
risk of MI and the magnitude of this effect.
Two studies that examined the association of allopur-
inol with MI provided contradictory results. In a
population-based case-control study, de Abajo et al. [16]
reported that allopurinol was associated with a lower
risk of MI with a hazard ratio (HR) of 0.52. This contra-
dicts the finding of an increased HR of 1.25 for a cardio-
vascular event requiring hospitalization (including MI,
stroke, hypertension, etc.) with allopurinol use in a
population-based study of patients with gout by Kok et
al. [17]. Compared to the positive study with only MI as
an outcome [16], the study by Kok et al. included a more
diverse (composite) outcome, used a prevalent rather
than an incident user design, and was limited to patients
with gout [17]. The study by de Abajo et al. was limited
to non-fatal MI and used a case-control design, which
are important study limitations [16]. Thus, both studies
had important limitations that make the interpretation
of study results difficult. The contradictory findings leave
an average reader unclear about whether allopurinol use
reduces the risk of MI or not. To our knowledge, it is
also not known whether the MI risk reduction with allo-
purinol varies by certain patient characteristics, such as
age, gender, and race.
Therefore, our objective was to assess whether allopur-
inol use was associated with a reduction in the risk of
MI in the elderly. We hypothesized that (1) allopurinol
use and (2) allopurinol use duration will each be inde-
pendently associated with a reduction in the risk of MI.
We also explored whether MI risk reduction with allo-
purinol varies by age, gender, and race.
Methods
Study cohort and population of interest
This retrospective cohort study used claims data from
the 5 % random sample of Medicare beneficiaries from
2006 to 2012. Data were obtained from the Centers
for Medicare and Medicaid Services (CMS) Chronic
Condition Data Warehouse. The insurance claims for
each beneficiary including inpatient, outpatient, skilled
nursing facility, noninstitutional provider, home
health, hospice, durable medical equipment services,
and prescription drugs were extracted alongside bene-
ficiary’s demographic information. Eligible subjects for
the cohort study were: Medicare beneficiaries who
were 65 years of age or older; lived in the US; were en-
rolled continuously in traditional Medicare fee-for-
service and pharmacy coverage (Parts A, B, and D)
and not enrolled in Medicare Advantage Plan, who
had new treatment with allopurinol (defined in the
section below). The Institutional Review Board at the
University of Alabama at Birmingham approved the
study.
Exposure definition and covariates
We defined new allopurinol treatment as a new-filled
allopurinol prescription, with no allopurinol prescription
filled during a look-back baseline period of 365 days.
Each day of observation within each episode was labeled
as exposed or non-exposed based upon the days supply
for allopurinol prescription in pharmacy records after
the beginning of the episode. We allowed up to 30 days
stock carry over. Patients were considered exposed for
30 days after the end of the days supply to capture the
attributable events, after which a new continuous allo-
purinol exposure period started. We categorized allopur-
inol use duration as none, 1–180 days, 181 days to
2 years, and longer than 2 years. A patient could con-
tribute multiple allopurinol treatment episodes during
different time periods.
We obtained several covariates from the Medicare de-
nominator file: age at the index date of each episode,
gender, race/ethnicity, residence, and comorbidity scores
in the baseline period for each allopurinol treatment epi-
sode, which were derived using Charlson-Romano co-
morbidity index score, a validated measure of medical
comorbidity developed for claims data [18]. We also ad-
justed for the use of medications for cardiovascular dis-
eases (beta-blockers, angiotensin-converting enzyme
(ACE) inhibitors, statins, and diuretics).
Outcome
The study outcome was incident MI, defined as the first
incidence of MI during the study period after the initi-
ation of a new allopurinol prescription, identified by the
presence of International Classification of Diseases,
ninth revision, common modification (ICD-9-CM) code,
410.x1. Patients had to have no MI in the baseline
period of 365 days. The follow-up for each treatment
episode began on the earliest allopurinol treatment initi-
ation date during the study period and ended on the
earliest of the first date of MI, the first date of losing full
Medicare coverage, the date of death, or the end of the
study (31 December 2012).
Statistical analyses
We calculated summary statistics for the cohort, by occur-
rence versus non-occurrence of MI, and by allopurinol ex-
posure versus not. We performed Cox proportional
hazard regression models to assess the association of inci-
dent allopurinol exposure (yes/no) or the duration of allo-
purinol use and incident MI. Multivariable analysis
adjusted for age, gender, race, Charlson-Romano comor-
bidity score, and the use of medications for cardiovascular
diseases (beta-blockers, ACE inhibitors, statins, and di-
uretics). We accounted for correlated episodes (patients
could possibly contribute more than one episode of new
allopurinol use) using the Huber-White “Sandwich”
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variance estimator [19] and calculated robust standard er-
rors for all estimates. HRs and 95 % confidence intervals
(CIs) were calculated.
Sensitivity analyses were performed adjusting for: 1)
individual CAD risk factors including hypertension,
hyperlipidemia, diabetes, and smoking, instead of
Charlson-Romano comorbidity index; (2) additionally
adjusting the previous sensitivity analyses for CAD and
peripheral vascular disease (PVD); and (3) additionally
adjusting the previous sensitivity analyses for aspirin and
colchicine use.
In multivariable-adjusted subgroup analyses by age,
gender, and race, the main model was adjusted for all
factors (age, gender, race, Charlson-Romano comorbidity
score, use of cardiovascular medications, allopurinol use
or duration) except the factor of interest for each sub-
group analysis, respectively (age, gender, race).
Results
Characteristics of the patient population
There were 29,298 episodes of incident allopurinol use,
with no allopurinol use in the baseline period of 365 days
(Table 1). Of these, 1544 allopurinol use episodes ended
in an incident MI (5.3 % episodes), while the majority
(94.7 %) did not (Fig. 1). Compared to incident allopur-
inol episodes that did not end in an MI, allopurinol epi-
sodes ending with an incident MI were associated with
older age, a higher Charlson-Romano index (4.24 versus
2.98), male gender, and non-White race (Table 1). Table 2
shows MI incidence rate by allopurinol use and the dur-
ation of allopurinol use.
Allopurinol use, allopurinol duration, and the risk of
myocardial infarction
In patients with a new MI, those using allopurinol were
older and had a higher Charlson comorbidity index
compared to patients not using allopurinol (Table 3).
Univariate associations are shown in Table 4. In
multivariable-adjusted analyses, allopurinol use was as-
sociated with 15 % reduction in hazard of MI, with a HR
of 0.85 (95 % CI, 0.77 to 0.95). Other factors associated
with higher hazard of MI were: age 75 to <85 years and
≥85 years, male gender, higher Charlson index score,
and the use of an ACE inhibitor (Table 4).
In a separate multivariable-adjusted model, compared
to no allopurinol use, we found that longer allopurinol
use duration was associated with a lower hazard of MI:
181 days to 2 years, 0.83 (95 % CI, 0.72 to 0.95) and
>2 years, 0.70 (95 % CI, 0.56 to 0.88) (Table 4); allopur-
inol use for 1–180 days was not associated with reduc-
tion in hazard of MI.
Sensitivity analyses limited to patients with gout
showed that the findings were unchanged with minimal/
no attenuation of HRs (Table 5); 83 % of allopurinol
users had a diagnosis of gout. Sensitivity analyses were
performed adjusting for CAD risk factors, i.e., hyperten-
sion, hyperlipidemia, diabetes, and smoking (instead of
Charlson-Romano index), and these confirmed the main
findings: allopurinol use, 0.86 (0.77, 0.95), and allopur-
inol use duration (1–180 days, 0.97 (0.83, 1.13); 181 days
to 2 years, 0.84 (0.73, 0.97); and >2 years, 0.69 (0.55,
0.87)) were significantly associated. Additional file 1
shows this in more detail. Sensitivity analyses that ad-
justed for PVD and CAD in addition to CAD risk factors
confirmed the associations of allopurinol use and dur-
ation of allopurinol use with MI risk, with no further at-
tenuation of HRs (see Additional file 2). Sensitivity
analyses that further adjusted for aspirin and colchicine
use showed minimal/no attenuation of HRs for allopur-
inol use and allopurinol use duration; neither aspirin,
Table 1 Demographic and clinical characteristics of episodes of




All observations No Yes
Total episodes, n 29,298 27,754 1544
Age (years), mean
(SD)
76.6 (7.4) 76.5 (7.4) 78.1 (7.6) <0.0001
Gender, n (%) 0.57
Male 14,502 (49.5) 13,727
(49.5)
775 (50.2)






White 23,131 (79.0) 21,922
(79.0)
1209 (78.3)
Black 3583 (12.2) 3,374 (12.2) 209 (13.5)
Hispanic 613 (2.1) 578 (2.1) 35 (2.3)
Asian 1,281 (4.4) 1,224 (4.4) 57 (3.7)
Native American
100 (0.3) 93 (0.3) 7 (0.5)
Other/unknown
590 (2.0) 563 (2.0) 27 (1.7)
Region, n (%) <0.0001
Northeast 4736 (16.2) 4428 (16.0) 308 (20.0)
Midwest 7409 (25.3) 7003 (25.2) 406 (26.3)
South 11,797 (40.3) 11,220
(40.4)
577 (37.4)




3.65 (3.23) 3.59 (3.21) 4.79 (3.41) <0.0001
*No baseline MI within 365 days before the index date of allopurinol episode
Significant differences and p values are in bold
SD standard deviation
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nor colchicine were significant in this model that
adjusted for other covariates including CAD and PVD
(see Additional file 3).
Subgroup analyses by age, gender, and race for risk
reduction by allopurinol use duration
In multivariable-adjusted subgroup analyses by age, gen-
der, and race, allopurinol use durations of 181 days to
2 years and >2 years were associated with a reduction of
hazard of MI, most evident for the age groups 65–74
and ≥85 years, male gender, and Blacks (Fig. 2).
Discussion
In this study of Medicare claims we found that allopur-
inol use was independently associated with a lower risk
of an incident MI. Compared to patients who did not
use allopurinol, new allopurinol users had a 15 % lower
hazard of an incident MI. We also found that a longer
duration of allopurinol use was associated with a greater
risk reduction in hazard for an incident MI, i.e., allopur-
inol use durations of 0.5–2 years and >2 years was asso-
ciated with a 17 % and 30 % reduced hazard of an
incident MI. Our study provides robust evidence of MI
risk reduction with allopurinol use and suggests that it
may have a cardioprotective action. Several study find-
ings merit further discussion.
In previous studies, allopurinol use was associated
with a 48 % reduction in the hazard (HR, 0.52) for an in-
cident non-fatal MI using a Spanish database [16] versus
a 25 % increase in the hazard (HR, 1.25) of a cardiovas-
cular event requiring hospitalization (including MI,
hypertension, stroke, etc.) in Taiwanese patients with
gout [17]. The study showing an increased risk included
a composite cardiovascular outcome (more diverse than
Fig. 1 Flow-chart of study cohort of incident allopurinol users from 2006 to 2012 for a baseline of 365 days. A + B + C-HMO, DC, MI myocardial
infarction, Nb, NE number of episodes, Np, Number of prescriptions, Nb, Number of beneficiaries
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MI) and used a prevalent user (rather than an incident
user) design, both of which may have led to the lack of
observation of a protective effect for MI [17]. On the
other hand, the study by de Abajo et al. showing a pro-
tective allopurinol effect used a case-control study with
matching (a less robust study design) and was limited to
non-fatal MI, but used an incident user design [16]. The
contradictory evidence from two population-based stud-
ies indicated that more evidence that is robust was
needed, which will be crucial in deciding whether allo-
purinol use reduces the risk of MI or not. Other studies
have shown a beneficial effect of allopurinol use (versus
non-use) on mortality [20–22], heart failure readmission
or death [23], and overall cardiovascular outcomes (in-
cluding, but not limited to, MI) in patients with chronic
kidney disease [24]; however, none specifically assessed
MI only. A randomized, placebo-controlled, crossover
trial included 65 adults with angiographically docu-
mented CAD, a positive exercise tolerance test, and
stable chronic angina pectoris and randomized them to
allopurinol (600 mg per day) or placebo for 6 weeks be-
fore crossover [13]. Allopurinol statistically significantly
increased the median time to ST depression versus pla-
cebo (p = 0.0002; difference 43 s) and median total exer-
cise time versus placebo (p = 0.0003) [13] showing its
cardioprotective effect, providing one potential mechan-
ism of the benefit we demonstrated. Similarly, a study
comparing allopurinol to placebo in heart failure failed
to show any benefit of allopurinol to placebo in patients
with reduced ejection fraction [25].
Our finding of a reduction in the risk of MI with allo-
purinol use in the elderly is based on a rigorous meth-
odological approach using an incident user design. Use
of a representative sample, adjustment for multiple co-
variates and potential confounders, and the robustness
of estimates in sensitivity analyses, leads us to believe
that our study findings are likely accurate and support a
potential cardioprotective effect of allopurinol. To our
knowledge, our study is amongst the first studies in the
elderly population that show that allopurinol use is asso-
ciated with a reduction in the risk of MI.
The mechanism of reduction in MI risk with allopur-
inol may be multi-fold. The anti-oxidant action of allo-
purinol [26–32] may be responsible for improving
cardiac contractile function and preventing MI, similar
to its beneficial effect on the progression of post-
ischemic cardiomyopathy in mice [33]. Allopurinol im-
proves endothelial function in renal failure, diabetes,
sleep apnea, and heart failure [8–12, 34–43], also con-
firmed in a recent meta-analysis [44]. These mechanisms
may delay the progression of atherosclerosis and/or pre-
vent plaque instability [45]. Clinically, allopurinol has an
anti-ischemic action in patients with stable, chronic an-
gina [13], is associated with a reduction in left
Table 3 Demographic characteristics and prevalence of
comorbidities by allopurinol use in episodes with incident
myocardial infarction (MI)









76.5 (7.4) 77.6 (7.5) 78.4 (7.6) 0.046
Gender 0.13
Male 13,727 (49.5) 290 (47.8) 485 (51.8)
Female 14,027 (50.5) 317 (52.2) 452 (48.2)
Race 0.07
White 21,922 (79.0) 459 (75.6) 750 (80.0)
Black 3374 (12.2) 97 (16.0) 112 (12.0)




3.65 (3.23) 4.52 (3.32) 4.96 (3.47) 0.01
Comorbidity
Diabetes 11076 (39.91) 290 (47.8) 482 (51.4) 0.16
Hypertension 23456 (84.5) 544 (89.6) 811 (89.6) 0.07
CVD 3442 (12.4) 106 (17.5) 184 (19.6) 0.28
PVD 4631 (16.7) 133 (21.9) 247 (26.4) 0.047
All numbers are n (%), unless specified otherwise
P value compares episodes with versus without allopurinol in patients who
had an MI
Significant differences and p values are in bold
CVD cerebrovascular disease, PVD peripheral vascular disease, SD
standard deviation
Table 2 Incidence rate of myocardial infarction (MI) with
incident allopurinol exposure* (yes versus no) and different
allopurinol use duration periods
Person-days
of follow-up
MI cases MI incidence rate per
1,000,000 person-days
Allopurinol use
Yes 12,877,451 937 73
No 8,327,742 607 73
Allopurinol use duration
0 days 8,327,742 607 73
1–180 days 5,902,851 514 87
181 days to 2 years 5,127,382 326 64
>2 years 1,847,218 97 53
*Baseline period was defined as 365 days during which patients could not
have had an MI; baseline period for allopurinol was also 365 days before the
index allopurinol prescription during which the patient could not have had a
filled/refilled allopurinol prescription
Allopurinol use duration of “0 days” use represents the period where a person
was not using allopurinol. This could be because they had not received their
first prescription when we started observing them or because they went more
than 30 days without getting a new prescription; they would begin
contributing to the “0 days” category on day 31 of interruption of their
allopurinol prescription
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ventricular mass in patients with diabetes [14] and heart
disease [15], and with a reduction in blood pressure [46,
47], which are potential mechanisms for its cardiopro-
tective action. Other mechanisms of action for allopur-
inol include decreased macrophage interleukin 1-beta
(IL1β) secretion upon the activation of NLRP3 inflam-
masome [48, 49], and the impairment in CD36-mediated
TLR4/6-IRAK4/1 signaling [50], mechanisms that may
contribute to cardiac risk [51].
Another important study finding was that the dur-
ation of allopurinol use was associated with a dose-
dependent reduction in MI risk. In particular, compared
to non-use, longer allopurinol use duration of >6 months
to 2 years and >2 years were each associated with an
independent reduction in the hazard of MI of 17 % and
30 %, respectively (HRs, 0.83 and 0.70). Surprisingly,
allopurinol use <6 month was not associated with any
reduction in the risk of MI, which might indicate a
threshold of 6-month use for preventing MI. The re-
duction in hazard showed a response-gradient, which
provides further support for the protective effect of
allopurinol on incident MI, seen previously where long-
term allopurinol use was associated with a lower hazard
of cardiovascular events (including MI) at 0.43 (95 %
CI, 0.21–0.88; p = 0.02) in an open-label extension of a
randomized study [52]. Thus, longer term allopurinol
use seems to be cardioprotective in patients with gout.
Further support for a dose-response relationship for
allopurinol use duration for cardioprotection is evident
by observations of lower mortality risk in heart failure
patients [22] and lower MI risk in the general popula-
tion [16] with high-dose compared to low-dose allopur-
inol use. Whether the risk/benefit ratio of allopurinol
becomes favorable due to potential cardioprotection in
patients with asymptomatic hyperuricemia (without
gout) remains to be seen.
Table 4 Incident allopurinol use and the risk of incident myocardial infarction (MI)*
Univariate Multivariable-adjusted (model 1)** Multivariable-adjusted (model 2)**
HR (95 % CI) P value HR (95 % CI) P value HR (95 % CI) P value
Age (in years)
65 to <75 Ref Ref Ref
75 to <85 1.45 (1.29,1.62) <0.0001 1.36 (1.21, 1.52) <0.0001 1.36 (1.21, 1.52) <0.0001
≥85 2.08 (1.81, 2.38) <0.0001 1.92 (1.67, 2.21) <0.0001 1.92 (1.67, 2.21) <0.0001
Gender
Male Ref Ref Ref
Female 0.96 (0.87, 1.06) 0.46 0.87 (0.79, 0.96) 0.007 0.87 (0.79, 0.96) 0.007
Race
White Ref Ref Ref
Black 1.18 (1.02, 1.37) 0.02 1.14 (0.98, 1.32) 0.09 1.13 (0.97, 1.31) 0.11
Other 0.93 (0.78, 1.12) 0.45 0.93 (0.77, 1.11) 0.41 0.92 (0.77, 1.11) 0.37
Charlson- Romano index score 1.15 (1.14, 1.17) <0.0001 1.15 (1.13, 1.16) <0.0001 1.15 (1.13, 1.16) <0.0001
Statins 0.86 (0.66, 1.11) 0.23 0.85 (0.66, 1.11) 0.23 0.85 (0.65, 1.11) 0.22
Beta blockers 1.05 (0.82, 1.33) 0.72 1.02 (0.79, 1.31) 0.90 1.01 (0.79, 1.31) 0.91
Diuretics 0.92 (0.73, 1.17) 0.51 0.84 (0.66, 1.08) 0.18 0.84 (0.66, 1.08) 0.17
ACE inhibitors 1.33 (1.03, 1.70) 0.03 1.51 (1.17, 1.95) 0.002 1.51 (1.16, 1.95) 0.002
Allopurinol use 0.88 (0.79, 0.99) 0.02 0.85 (0.77, 0.95) 0.004 - -
Allopurinol use duration
0 days Ref - - Ref
1–180 days 1.00 (0.86, 1.16) 0.99 - - 0.98 (0.84, 1.14) 0.76
181 days to 2 years 0.87 (0.76, 1.01) 0.06 - - 0.83 (0.72, 0.95) 0.009
>2 years 0.71 (0.56, 0.89) 0.003 - - 0.70 (0.56, 0.88) 0.002
*Incident MI is defined as no MI within the baseline period of 365 days before the index date of allopurinol episode
**Model 1 = allopurinol use (yes versus no) + age + race + gender + Charlson-Romano index score + beta blockers + diuretics + ACE inhibitors + statins
**Model 2 = allopurinol use duration + age + race + gender + Charlson-Romano index score + beta blockers + diuretics + ACE inhibitors + statins
Significant odds ratios and p values are in bold
Allopurinol use duration of “0 days” represents the period where a person was not using allopurinol. This could be because they had not received their first
prescription when we started observing them or because they went more than 30 days without getting a new prescription; they would begin contributing to the
“0 days” category on day 31 of interruption of their allopurinol prescription
- Not in the model, ACE angiotensin-converting enzyme, CI confidence interval, HR hazard ratio, Ref reference category
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The greatest reductions in the hazard of MI with
allopurinol exposure were noted in those aged 65–74
and ≥85 years, those of female gender, and those of
Black race, another interesting finding which needs
confirmation and further study. A greater benefit in
the elderly and a racial minority is particularly inter-
esting, since these groups are usually at higher risk of
worse MI outcomes [53, 54].
Our study has several strengths and limitations. Despite
our efforts to control for various confounders, our study is
subject to potential residual confounding due to the co-
hort study design. To avoid this bias, we controlled for
multiple potential confounders and performed multiple
sensitivity analyses that supported the robustness of our
findings. Second, our database lacked information on
other risk factors, such as over the counter aspirin use,
body mass index and diet components, which can be
viewed as risk factors for MI; however, risk reduction was
confirmed in analyses adjusted for other traditional CAD
risk factors including hypertension, hyperlipidemia, dia-
betes, and smoking, and in models that additionally ad-
justed for aspirin use (by prescription), and other cardiac
and gout medications. Third, the number of MI events
may have been too low to detect statistical significance
of findings in certain subgroups, i.e., type II error; avail-
ability of the entire dataset would likely have overcome
this limitation. However, use of a national 5 % Medicare
sample is a standard approach in epidemiological re-
search [55, 56], and we had in excess of 1500 events for
the main analyses. Limited resources prevented us from
analyses of 100 % Medicare data.
Fourth, the Medicare data do not allow us to investi-
gate why allopurinol was prescribed and, although we
know that 83 % of allopurinol users in our study had a
diagnosis of gout, specific reasons for its use are not
known and likely included other conditions such as
Table 5 Incident allopurinol use and the risk of incident myocardial infarction (MI)* limited to patients with a diagnosis of gout
Univariate Multivariable-adjusted (model 3)** Multivariable-adjusted (model 4)**
HR (95 % CI) P value HR (95 % CI) P value HR (95 % CI) P value
Age (in years)
65 to <75 Ref Ref Ref
75 to <85 1.46 (1.29, 1.65) <0.0001 1.37 (1.21, 1.55) <0.0001 1.37 (1.21, 1.55) <0.0001
≥85 2.04 (1.76, 2.36) <0.0001 1.88 (1.62, 2.19) <0.0001 1.88 (1.62, 2.19) <0.0001
Gender
Male Ref Ref Ref
Female 0.98 (0.88, 1.10) 0.77 0.88 (0.79, 0.99) 0.03 0.88 (0.79, 0.99) 0.03
Race
White Ref Ref Ref
Black 1.22 (1.05, 1.43) 0.01 1.16 (0.10, 1.36) 0.06 1.16 (0.99, 1.35) 0.07
Other 0.84 (0.70, 1.06) 0.16 0.86 (0.70, 1.05) 0.14 0.85 (0.69, 1.05) 0.12
Charlson- Romano index score 1.15 (1.14, 1.1.7) <0.0001 1.15 (1.13, 1.16) <0.0001 1.15 (1.13, 1.16) <0.0001
Statins 0.87(0.65, 1.15) 0.31 0.84 (0.63, 1.13) 0.25 0.84 (0.63, 1.12) 0.24
Beta blockers 1.06 (0.81, 1.38) 0.68 1.01 (0.76, 1.34) 0.96 1.01 (0.76,1.34) 0.97
Diuretics 1.00 (0.77, 1.30) 0.99 0.91 (0.70, 1.20) 0.50 0.91 (0.69, 1.19) 0.49
ACE inhibitors 1.43 (1.09, 1.88) 0.01 1.61 (1.22, 2.13) 0.0008 1.61 (1.22, 2.12) 0.009
Allopurinol use 0.84 (0.74, 0.94) 0.003 0.81 (0.72, 0.91) 0.0004 - -
Allopurinol use duration
0 days Ref - - Ref
1–180 days 0.94 (0.80, 1.11) 0.47 0.92 (0.78, 1.09) 0.33
181 days to 2 years 0.83 (0.72, 0.97) 0.01 0.79 (0.68, 0.92) 0.002
> 2 years 0.68 (0.54, 0.86) 0.001 0.68 (0.53, 0.85) 0.001
*Incident MI is defined as no MI within the baseline period of 365 days before the index date of allopurinol episode
**Model 3 = allopurinol use (yes versus no) + age + race + gender + Charlson-Romano index score + beta blockers + diuretics + ACE inhibitors + statins
**Model 4 = allopurinol use duration + age + race + gender + Charlson-Romano index score + beta blockers + diuretics + ACE inhibitors + statins
Significant odds ratios and p values are in bold
- Not in the model, ACE angiotensin-converting enzyme, CI confidence interval, HR hazard ratio, Ref reference category
Allopurinol use duration of “0 days” represents the period where a person was not using allopurinol. This could be because they had not received their first
prescription when we started observing them or because they went more than 30 days without getting a new prescription; they would begin contributing to the
“0 days” category on day 31 of interruption of their allopurinol prescription
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hyperuricemia without gout, metabolic syndrome, renal
stones, tumor lysis syndrome, etc. However, regardless
of the reason for allopurinol prescription, our observa-
tion of its beneficial effect is generalizable to all US
elderly who use allopurinol. We also showed with sensi-
tivity analyses that these effects were similar in magni-
tude for elderly Americans with gout who used
allopurinol. Finally, these data are derived from
Fig. 2 Multivariable-adjusted hazard ratios of MI by duration of allopurinol use by a age group, b gender and c race. For the multivariable-adjusted
subgroup analyses by age, gender, and race, the main model was adjusted for all factors (age, gender, race, and Charlson-Romano comorbidity score)
except the factor of interest, respectively, which was used to perform stratified analysis (age, gender, race)
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Medicare, and can only be generalized to the US elderly
population, not the US general population. Fifty percent
of the elderly using allopurinol are female, which is dif-
ferent to the usual institutional cohorts of allopurinol
users dominated by men, since these studies include pa-
tients from all age groups; however, our sample is that of
all US elderly aged 65 years and older.
Strengths of the study included the use of a representative
US population, the ability to control for the common MI
risk factors, robustness of findings in multiple sensitivity
models, the use of an incident user design to avoid the
biases of prevalent user design, and the examination of both
the allopurinol exposure and the duration of allopurinol use.
Conclusions
In conclusion, this study shows the cardioprotective effect
of allopurinol in preventing MI in the elderly, and shows
that this protective effect is evident after 6 months of allo-
purinol use and is more pronounced after 2 years of allo-
purinol use. The greatest reductions in the hazard of MI
with allopurinol exposure were noted in age groups 65–74
and ≥85 years, females, and Black race. We used an inci-
dent user design and the associations noted were robust
in multiple sensitivity analyses. These findings are
generalizable to all US elderly people aged 65 years and
older. Future studies need to examine the potential mech-
anisms of this cardioprotective effect of allopurinol use,
which may uncover pathways either through urate reduc-
tion and/or other independent effects of allopurinol [57].
Additional files
Additional file 1: Sensitivity analysis adjusted for CAD risk factors.
Association of potential risk factors with the hazard of incident MI in
patients who received allopurinol with no MI within 365 days before the
index date of allopurinol use episode. This file shows that when the main
model was additionally adjusted for CAD risk factors such as diabetes,
hypertension, tobacco use disorder, and hyperlipidemia, instead of the
Charlson-Romano index, the relationship of allopurinol use and allopurinol
use duration with the risk of MI did not change. (DOCX 21 kb)
Additional file 2: Sensitivity analysis adjusted for CAD risk factors, CVD
and PVD. Association of various risk factors with the hazard of incident MI
in patients who received allopurinol with no MI within 365 days before
the index date of allopurinol episode. This file shows that when the main
model was additionally adjusted for CAD risk factors (diabetes, hypertension,
tobacco use disorder, and hyperlipidemia) instead of the Charlson-Romano
index and CAD and peripheral vascular disease, the relationship of allopurinol
use and allopurinol use duration with the risk of MI did not change.
(DOCX 23 kb)
Additional file 3: Sensitivity analysis adjusted for CAD risk factors, CVD,
PVD, aspirin and colchicine use. Association of various risk factors with
the hazard of incident MI in patients who received allopurinol with no MI
within 365 days before the index date of allopurinol episode. This file
shows that when the main model was additionally adjusted for CAD risk
factors (diabetes, hypertension, tobacco use disorder, and hyperlipidemia)
instead of the Charlson-Romano index, CAD and peripheral vascular
disease, and aspirin and colchicine use, the relationship of allopurinol use
and allopurinol use duration with the risk of MI did not change.
(DOCX 23 kb)
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